Guide detail

Retatrutide and AOD-9604

This protocol outlines the safe and effective use of Retatrutide (a GLP-1, GIP, and glucagon receptor agonist) and AOD-9604 (a modified fragment of human growth hormone) for metabolic enhancement, fat loss, and potential muscle preservation. The combination leverages synergistic mechanisms to optimize body composition.

  1. Preparation:
    • Ensure all materials are sterile: insulin syringes (29-31G), alcohol swabs, bacteriostatic water, and peptide vials.
    • Reconstitute peptides:
      • Retatrutide: Add 1 mL bacteriostatic water to a 5 mg vial (yielding 5 mg/mL).
      • AOD-9604: Add 2 mL bacteriostatic water to a 5 mg vial (yielding 2.5 mg/mL).
    • Store reconstituted peptides at 2-8°C (refrigerated) for up to 30 days.
  2. Dosing Schedule:
    • Retatrutide: Start at 0.5 mg/week (0.1 mL of reconstituted solution) subcutaneously (SC). Titrate by 0.5 mg every 2 weeks based on tolerance, max 4 mg/week.
    • AOD-9604: 300 mcg/day (0.12 mL of reconstituted solution) SC, ideally administered in the morning or pre-workout.
  3. Administration:
    • Rotate injection sites (abdomen, thighs, or upper arms) to avoid lipohypertrophy.
    • Pinch skin, inject at 45-90° angle, and aspirate lightly to ensure no blood return.
  4. Cycle Length:
    • Run for 8-12 weeks, followed by a 4-week washout to assess tolerance and reset receptors.
  5. Monitoring:
    • Track body composition (DEXA or calipers), fasting glucose, and appetite changes weekly.
    • Adjust diet to prioritize protein (2.2 g/kg lean mass) and electrolytes to mitigate nausea (common with Retatrutide).
  6. Post-Cycle:
    • Gradually taper Retatrutide by 0.5 mg/week to avoid rebound hunger. AOD-9604 can be discontinued abruptly. - Synergy: Retatrutide’s multi-receptor agonism enhances insulin sensitivity and satiety, while AOD-9604 promotes lipolysis without systemic growth hormone effects.,- Timing: Administer AOD-9604 at least 2 hours apart from Retatrutide to avoid overlapping peak effects.,- Contraindications: Avoid with history of medullary thyroid carcinoma or MEN-2 (Retatrutide risk).

Warnings

  • Hypoglycemia risk: Monitor glucose if combining with other glucose-lowering agents.
  • Avoid alcohol: May exacerbate Retatrutide’s gastrointestinal side effects.
  • Pregnancy/Breastfeeding: Peptides are contraindicated due to unknown safety profiles.
  • Consult a physician before use, especially with pre-existing metabolic conditions.

References

  • Retatrutide (LY3437943) Phase 2 Trial: NCT04881760
  • AOD-9604 Mechanism: Heffernan et al., 2001 (PMID: 11368342)
  • GLP-1/GIP/Glucagon Tri-Agonist Review: Finan et al., 2020 (PMID: 32029622)